medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2017, Number 4

<< Back Next >>

Rev Mex Urol 2017; 77 (4)

Efficacy of intravesical therapy with mitomycin C in patients with superficial urothelial carcinoma of the bladder after transurethral resection of bladder tumor and symptomatic correlation with tumor recurrence

Velázquez-Macías RF, Monroy-Bolaños GE

Language: Spanish
References: 11
Page: 258-264
PDF size: 278.51 Kb.


ABSTRACT

Background:Bladder cancer is the second most frequent urologic cancer worldwide (3.3%). Transurethral resection of bladder tumor followed by adjuvant intravesical therapy with mitomycin C is a therapeutic option when the cancer is non-muscle-invasive.
Objetive: To evaluate the efficacy of mitomycin C after transurethral resection of superficial bladder tumor and to identify the risk factors associated with tumor recurrence.
Material and Method: A retrospective, analytic, observational, and longitudinal study was conducted on patients with superficial bladder cancer that underwent transurethral resection of bladder tumor and then received intravesical therapy with mitomycin C. The patients were divided into group 1: with no tumor recurrence and group 2: with tumor recurrence. The study variables were: age, sex, tumor-associated symptomatology, histologic grade, recurrence, and adverse effects from mitomycin C. The Student’s t test, chi-square test, and Spearman’s rho were the statistical tests used for the data analysis.
Results: There were 20 patients in group 1 and 8 in group 2. The mean age of the group 1 patients was 67.7 and 66.8 years, for women and men, respectively, and was 66 and 62.8 years in group 2 (χ2, p = 0.410). Mean follow-up in group 1 was 41.4 months, and 43.8 months in group 2. Male sex predominated in group 1 (60%) and female sex in group 2 (62.25%), with no statistical difference between the two groups (χ2, p=0.410). The mean presentation time of recurrence was 10.3 months. Symptoms improved in G1 after treatment. There was clinical improvement in dysuria (χ2, p=0.006), urethral burning sensation (χ2, p=0.005), and pollakiuria (χ2, p=0.030) that was statistically significant. In the G2 group hematuria, urgency, nocturia, and suprapubic pain decreased and dysuria, urethral burning sensation, and pollakiuria remained unchanged. Bladder tenesmus increased, but without statistical significance. In relation to tumor recurrence, there was a positive association with hematuria (Spearman’s rho, p=0.000), dysuria (Spearman’s rho, p=0.004), urethral burning sensation (Spearman’s rho, p=0.004), and pollakiuria (Spearman’s rho, p = 0.030) after treatment. There was also a positive association with pretreatment suprapubic pain (Spearman’s rho, p=0.026) and tumor stage (Spearman’s rho, p=0.001). Fifteen patients (53.6%) had adverse effects from mitomycin C and the most frequent was urinary tract infection, followed by urethral stricture.
Conclusions: Mitomycin C was effective for controlling and reducing symptoms related to bladder cancer.


REFERENCES

  1. Organización Mundial de la Salud. Cáncer. Nota descriptiva No. 297. [En línea] Dirección URL: . (Consulta: 7 de enero de 2011).

  2. Asociación española contra el cáncer. Cáncer de vejiga. Incidencia. [En línea] Dirección URL: . (Consulta: 1 de abril de 2014)

  3. Jiménez MA, Solares M, Martínez P, Martínez J, Hinojosa J, Zamora J, Rivera L.. Oncoguía. Cáncer de vejiga. Cancerología 2011;6:33-36.

  4. Sánchez H. Cáncer de vejiga. En: Manual Práctico de Urología. 1ª ed. México: Cuellar Ayala, 2014;447.

  5. Wein A, Kavoussi L, Novick A, Partin A, Peters G. Campbell/ Walsh Urología. 2012, 10ª edición. Ed. Philadelphia: Elsevier Saunders.

  6. Shen Z, Shen T, Guillaume M, O’Donnell, Au J. Intravesical treatments of bladder cancer: review. Pharm Res 2008;25(7):1500-1510.

  7. Advanced Bladder (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. Eur Urol 2005;48(2):189-201.

  8. Torres O, Jofre M, López F, Rodriguez H, Issolio J, Muñoz G, Marcoos M, Zalazar J, Obregón H. Cáncer de vejiga: incidencia en nuestro servicio. Revista de Posgrado de la VIa Cátedra de Medicina 2002;115:8-9.

  9. Jalón A, Fernández J, Escaf S, Álvarez M, Martín J, Regadera F. Efecto terapéutico de mitomicina C en el postoperatorio inmediato de pacientes con tumores vesicales no músculo invasores de riesgo intermedio. Actas Urol Esp 2008;32(9):894-903.

  10. Celaya M, Buil P, Garjón J, Espeja M, Martínez C. Evaluaciones de las reacciones adversas y la eficacia de la mitomicina y la BCG en el tratamiento intravesical del cáncer superficial de vejiga. Farm Hosp 1997;21(3):137-142.

  11. Shelley M, Mason M, Kynaston H. Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010;36(3):195-205.




2020     |     www.medigraphic.com